EXELIXIS, INC.EXEL

EXELIXIS, INC. Segments Disclosure

10-KFiled Feb 10, 20262 min read
SEGMENT REPORTING
We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our President and Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our President and Chief Executive Officer uses net income to monitor budget versus actual results for purposes of evaluating performance and to make decisions about the allocation of resources.
Our significant segment expenses that are regularly provided to our President and Chief Executive Officer and included in the measure of segment net income consist of consolidated expenses for our operational departments: drug discovery, development, and selling, general and administrative and other segment items.
The segment and consolidated net income, including significant segment expenses were as follows (in thousands):
 Year Ended December 31,
 202520242023
Revenues$2,320,126 $2,168,701 $1,830,208 
Less:
Cost of goods sold83,697 76,216 72,547 
Drug discovery89,931 94,842 215,085 
Development567,843 665,847 669,240 
Selling, general, and administrative446,536 428,962 470,680 
Other segment items(1)
260,126 298,350 231,678 
Interest income(69,213)(77,156)(86,543)
Provision for income taxes158,636 160,373 49,756 
Segment and consolidated net income$782,570 $521,267 $207,765 
_________________
(1) Other segment items include stock-based compensation, impairment of long-lived assets, restructuring expenses, other research and development expenses, including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other income (expenses), net.
All of our long-lived assets are located in the U.S. See “Note 3. Revenues” for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.
Free Sentinel

Want the next EXELIXIS, INC. segments disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment EXELIXIS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&ECommitmentsStock CompensationNew Standards